Item 7.01. Regulation FD Disclosure.
Louisa Daniels has ended her employment as Chief Legal Officer and General
Counsel of Recursion Pharmaceuticals, Inc. (the "Company"). We thank Ms. Daniels
for her substantial contributions to our mission, which include guiding the
Company through its transition into a public company and building a highly
effective legal team.
Also, on January 13, 2023, the Company appointed Nathan Hatfield to the position
of Senior Vice President, Head of Legal. Mr. Hatfield will assume all
responsibilities of Ms. Daniels, including joining our executive team. Mr.
Hatfield has held several critical leadership positions since joining the
Company in early 2017, most recently Senior Vice President of Legal and
Associate General Counsel. Prior to that, Mr. Hatfield was a corporate and
securities attorney at Wilson Sonsini, where he represented venture-backed
technology and life science companies through all stages of growth. Mr. Hatfield
has a bachelor's degree and a master's degree in Business Administration and a
Juris Doctorate from the University of Washington.
The information furnished pursuant to Item 7.01 on this Form 8-K, shall not be
deemed "filed" for purposes of Section 18 of the Securities Exchange Act of
1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities
of that section, nor shall it be deemed incorporated by reference into any other
filing under the Securities Act of 1933, as amended, or the Exchange Act, except
as expressly set forth by specific reference in such a filing.
Item 9.01. Financial Statements and Exhibits.
(d) Exhibits.
Exhibit Number Description
Cover Page Interactive Data File (embedded within the Inline XBRL
104 document)© Edgar Online, source Glimpses
RECURSION PHARMACEUTICALS, INC. 
